Skip to main content

BLTE · Belite Bio, Inc

Track BLTE — free
$127.38 -23.64 (-15.65%) At close · Nov 20
Market Cap
$5.17B
Shares
40.61M
Volume · Nov 20 1.04M Avg daily vol (3M) 194.38K

Price & Indicators

 

Key stats

Close
$127.38
Fri 20 Nov
Open
$129.00
Fri 20 Nov
Average volume, 30 days
203K
shares a session
Short interest
1.4M
3.4% of shares · 10.0 days to cover
Day range
$120.00$135.07
Open $129.00 Close $127.38
52-week closing range
$109.18$193.61
Close $127.38 34.2% under the high
Short volume, last session
66%
Last earnings
Nov 12, 2026
Price history
Apr 2022 to Nov 2026

Up next

Mar 1, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 20
Current report 6-K
FDA Extends Tinlarebant NDA Review by Three Months to May 12, 2027

The FDA extended the review period for the tinlarebant New Drug Application for Stargardt disease type 1 by three months, moving the PDUFA action date to May 12, 2027. If no major deficiencies are identified, the FDA plans to communicate proposed labeling requests by April 12, 2027.

2 source passages
the FDA has informed the Company that (i) it has extended the review period for the New Drug Application (NDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1) by three months, with the extended Prescription Drug User Fee Act (PDUFA) action date being May 12, 2027 if no major deficiencies are identified during FDA's ongoing review, the FDA plans to communicate proposed labeling requests and any anticipated postmarketing requirement requests, if necessary, with the Company by April 12, 2027. Open the document at this passage
Nov 12
Earnings call
FDA accepts NDA with priority review and no advisory committee

Beelite Bio reported FDA acceptance of its NDA for TeneraBand with priority review, a February 12, 2027 put-to-fit date and no advisory committee. Q3 GAAP net loss was $30.3 million; cash, cash equivalents and U.S. Treasury bills totaled $774 million.

4 source passages
Ladies and gentlemen, thank you for joining us, and welcome to the Beelite Bio third quarter 2026 earnings call. We were very excited to report in August that the FDA accepted our NDA for TeneraBand with priority review and a put-to-fit date of February 12, 2027. The FDA has also informed us that it will not convene an advisory committee meeting to discuss the NDA for TeneraBand in Stardust disease. GAAP net loss in the third quarter was $30.3 million compared to $21.7 million in 2025. We ended the quarter with $774 million in cash, cash equivalents, and U.S. Treasury bills, compared to $780 million in Q2, 2026. Open the document at this passage
Nov 12
Current report 6-K
Tinlarebant FDA review advances without advisory committee

Belite Bio said FDA will not convene an advisory committee for tinlarebant’s STGD1 NDA, with a PDUFA target action date of February 12, 2027. It reported a $30.3 million third-quarter net loss and $271.3 million cash and equivalents as of September 30, 2026.

5 source passages
In August 2026, the FDA accepted the NDA for tinlarebant in STGD1 and granted Priority Review, with an assigned PDUFA target action date of February 12, 2027. The Company has been informed by the FDA that it will not convene an advisory committee meeting to discuss the NDA for tinlarebant in STGD1. SAN DIEGO, November 12, 2026 - Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio^®^” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the third quarter ended September 30, 2026, and provided a business update. For the three months ended September 30, 2026, the Company reported a net loss of $30.3 million, compared to a net loss of $21.7 million for the same period in 2025. As of September 30, 2026, the Company had $271.3 million in cash and cash equivalents, compared with $352.9 million on December 31, 2025. Open the document at this passage
Oct 19
Current report 6-K
Shares to trade on Nasdaq Global Select Market from October 19, 2026

Belite Bio received Nasdaq approval to move its listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, the highest of the three Nasdaq tiers. Trading on the new market starts at the open on October 19, 2026, under the existing ticker BLTE.

3 source passages
Belite Bio, Inc issued a press release entitled “Belite Bio Announces Uplisting to the Nasdaq Global Select Market.” today announced that it has received approval from Nasdaq to transfer the listing of its securities from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the Nasdaq Global Select Market will commence at the open of market on October 19, 2026, under the Company’s existing ticker symbol “BLTE.” Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+21.6%
Year over year · more shares
Price change (1Y)
+16.7%
Trailing year
Short interest
3.4%
Latest settlement · 10.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross Death cross
Price vs 200-day avg −20%
below
Price vs 50-day avg −19%
below
RSI (14) 32
neutral
MACD trend Negative
52-week position 22%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −14%
trailing
6-month return −6%
trailing
YTD return −20%
this year
Relative strength +4%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) Death cross
50d $158 › 200d $159 — 200d above 50d
Institutional flow Accumulating
+20% holders QoQ · +28 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.40% of shares out · ▲ +8.9% MoM · 10.0 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
96 holders — near 3-yr high, broad support
Squeeze score 67
elevated · 0–100
Fundamentals
Weak
EPS growth −96%
Y/Y
Free cash flow $-37.1M
Balance sheet $352.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 55%
annualized · 1-yr
Max drawdown −34%
past year
ATR 7.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
Death cross Bearish
Price vs 200-day avg
−20% Bearish
Price vs 50-day avg
−19% Bearish
RSI (14)
32 Neutral
MACD trend
Negative Bearish
52-week position
22% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) Death cross
50d $158 › 200d $159 — 200d above 50d
Institutional flow Accumulating
+20% holders QoQ · +28 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
3.40% of shares out · ▲ +8.9% MoM · 10.0 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
96 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $109 Now $127 · 22% Range high $194
vs 200-day avg -20% vs 50-day avg -19% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BLTE
Belite Bio, Inc
this stock
$5.17B -20.4% — — 3.4%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
96
% held
23.2%
Net QoQ
-60.0K sh
Top holder
Darwin Global Management,…
Held Float
View
Held by Funds
Fund positions
23
View
Short & Settlement
Short Interest Rising
Shares short
1.4M
Days to cover
10.0d
Change
+113.0K sh
View
Short Volume
Short vol %
66%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
3.9K
Value
$605.6K
As of
Oct 21, 2026
View
Off-Exchange
Off-exchange %
51.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-77.6M
EPS diluted
$-2.31
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 20, 2026
This year
13

The FDA extended the review period for the tinlarebant New Drug Application for Stargardt disease type 1 by three months, moving the PDUFA action date to May 12, 2027. If no major deficiencies are identified, the FDA plans to communicate proposed labeling requests by April 12, 2027.

View
Proposed Sales
Value
$1.2M
Shares
9.6K
Filed
Oct 17, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
BLTE -22.5% -13.5% -5.6% -17.7% -20.4%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -13.9% -4.3% +3.6% -9.0% -21.5%
Key facts CIK 1889109 CUSIP 07782B104 13F (30d) 94 filings 93 filers Visit website Investor relations